UBS Group’s ARK Genomic Revolution ETF ARKG Stock Holding History

UBS Group’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-175,000	Closed	-$5.07M	–	10453
2025 Q4	$5.07M	Hold	175,000	–	–	﹤0.01%	4015
2025 Q3	$4.86M	Hold	175,000	–	–	﹤0.01%	4066
2025 Q2	$4.26M	Hold	175,000	–	–	﹤0.01%	4040
2025 Q1	$3.63M	Buy	+175,000	New	+$4.4M	﹤0.01%	4115
2024 Q1	–	Sell	-100,000	Closed	-$3.28M	–	9271
2023 Q4	$3.28M	Buy	+100,000	New	+$2.72M	﹤0.01%	3250
2022 Q3	–	Sell	-80,000	Closed	-$2.52M	–	10303
2022 Q2	$2.52M	Hold	80,000	–	–	﹤0.01%	2946
2022 Q1	$3.67M	Hold	80,000	–	–	﹤0.01%	2848
2021 Q4	$4.9M	Sell	80,000 -40,000	-33%	-$2.77M	﹤0.01%	2846
2021 Q3	$8.97M	Sell	120,000 -179,500	-60%	-$15.1M	﹤0.01%	2112
2021 Q2	$27.7M	Buy	299,500 +79,800	+36%	+$6.78M	0.01%	1237
2021 Q1	$19.5M	Buy	+219,700	New	+$21.8M	0.01%	1460

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

UBS Group's ARKG Position: Q1 2026 in Review

UBS Group reduced its ARK Genomic Revolution ETF (ARKG) stake by 30% in Q1 2026, selling an estimated $11.4M and leaving 907,084 shares worth $24M. The position accounts for ﹤0.01% of the portfolio, ranked #2388.

UBS Group first reported a position in ARKG in Q4 2014 and has held it in 40 quarters since. The position peaked at $138M in Q1 2021. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

UBS Group held 907,084 shares of ARK Genomic Revolution ETF worth $24M as of Q1 2026.
UBS Group sold 388,524 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $11.4M.
ARK Genomic Revolution ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2388 holding.
UBS Group first reported a position in ARK Genomic Revolution ETF in Q4 2014 and has held it in 40 quarters since.
UBS Group's ARK Genomic Revolution ETF position peaked at $138M in Q1 2021.
218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.